Finding the right affinity ligand pair is a bottleneck in immunoassay development where the Optimer platform can help. Whether you need an additional reagent to form an aptamer-antibody pair or…
When developing an aptamer to a protein target it’s important to keep in mind how you want to use it as much as what you want to bind. When developing…
Dr Daniel Wiseman is a Senior Clinical Lecturer at the University of Manchester, and a Consultant Haematologist at the Christie NHS Foundation. He is exploring Optimer® binders as…
23/05/2023 Aptamer Group, the developer of novel Optimer® binders to enable innovation in the life sciences industry, in partnership with Bioliquid Innovative Genetics and Anima Design of Spain, announce that they…
28/11/2022 Baroness Susan Greenfield opened the new site and presented on the challenges in scientific discovery Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in…
28/09/21 Aptamer Group, Ltd. the developer of Optimer®
02/10/2020 Aptamer Group, a York-based biotechnology company, has demonstrated the strength of the sector in the North of England with the appointment of six new scientists. Claire Jones (22), Callum Robson…
12th December 2019 Continuous improvement in imaging techniques have allowed biologists to explore with accurate methods to label cellular elements as they surpass the limit imposed by the…
14th November 2019 Flow cytometry has gained popularity and demand in the field of biology because of its accurate analysis and high throughput. The use of multiple lasers,…
4th October 2019 Isolating a single target from a complex sample can be challenging and is often a multi step process which requires increased specificity for the target….
